| Abstract | The article studies the use of autologous bone marrow transplantation to treat acute myeloid leukaemia when complete remission had been achieved and when no human leukocyte antigen-matched related donor was available. The study was conducted in a government hospital. Eight patients (median age, 34 years [range, 16-45 years]) with acute myeloid leukaemia in whom complete remission had been achieved were studied. Outcome measures include median time taken to reach neutrophil and platelet counts of (>_)0.5 x 10(9) /L and (>_)20 x 10(9) /L, respectively; mortality and relapse rates; and follow-up regimens used. Engraftment was successfully achieved in all patients and there were no early procedure-related mortalities. The median times required to reach a neutrophil count of (>_)0.5 x 10(9) /L and a platelet count of (>_)20 x 10(9) /L were 30 days (range, 18-36 days) and 38 days (range, 15-53 days), respectively. The median duration of hospital study was 37 days (range, 25-43 days). Two patients died of a relapse of leukaemia at 6 and 9 months post-transplantation. Two patients experienced relapses: one at 8 months post-transplantation, for which conventional chemotherapy was restarted, and one at 18 months; treatment with all-trans-retinoic acid and conventional chemotherapy achieved a third complete remission in the latter patient, who had acute promyelocytic leukaemia. continuous remission has been achieved in four of the eight patients after a median follow-up duration of 26 months (range, 6-43 months). |
|---|
